Clinically Meaningful Use of Blood Tumor Markers in Oncology

Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer

(2016) Rafael Molina et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Genetics of mCRPC tracked in ctDNA

(2016) Peter Sidaway   Nature Reviews Clinical Oncology

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

(2016) Jeanne Tie et al.   Science Translational Medicine

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

(2016) Jacob J. Chabon et al.   Nature Communications

ReCAP: Serum Tumor Marker Use in Patients With Advanced Solid Tumors

(2016) Melissa K. Accordino et al.   Journal of Oncology Practice

Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients

(2016) Kikuya Kato et al.   Scientific Reports

A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers

(2015) B. T. Li et al.   ANNALS OF ONCOLOGY

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) M. Ducreux et al.   ANNALS OF ONCOLOGY

Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) C. Parker et al.   ANNALS OF ONCOLOGY

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients

(2015) Laura Lupini et al.   BMC CANCER

Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China

(2015) Catharina M. Korse et al.   CLINICA CHIMICA ACTA

Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer

(2015) Dorit Di Gioia et al.   CLINICA CHIMICA ACTA

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

(2015) J. S. Frenel et al.   CLINICAL CANCER RESEARCH

Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass

(2015) Elizabeth Lokich et al.   GYNECOLOGIC ONCOLOGY

Seven Questions for Personalized Medicine

(2015) Michael J. Joyner et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening

(2015) Usha Menon et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials

(2015) Maria Schwaederle et al.   JOURNAL OF CLINICAL ONCOLOGY

Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study

(2015) Henrik Grönberg et al.   LANCET ONCOLOGY

Unknown

(2015) Jennifer Hardingham et al.   MOLECULAR MEDICINE

Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients

(2015) Sharon K. Huang et al.   Molecular Oncology

Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer

(2015) Kjersti Tjensvoll et al.   Molecular Oncology

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

(2015) Isaac Garcia-Murillas et al.   Science Translational Medicine

Late Relapse of Testicular Germ Cell Tumors

(2015) Matthew J. O’Shaughnessy et al.   UROLOGIC CLINICS OF NORTH AMERICA

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations

(2015) Simon Chang-Hao Tsao et al.   Scientific Reports

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

(2014) F. Cardoso et al.   ANNALS OF ONCOLOGY

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

(2014) F. Cardoso et al.   BREAST

An Official American Thoracic Society/American College of Chest Physicians Policy Statement

(2014) Renda Soylemez Wiener et al.   CHEST

Effect of 3 to 5 Years of Scheduled CEA and CT Follow-up to Detect Recurrence of Colorectal Cancer

(2014) John N. Primrose et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) J. A. Ledermann et al.   ANNALS OF ONCOLOGY

Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) R. Labianca et al.   ANNALS OF ONCOLOGY

S-100B: A Stronger Prognostic Biomarker than LDH in Stage IIIB–C Melanoma

(2013) K. P. Wevers et al.   ANNALS OF SURGICAL ONCOLOGY

Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer

(2013) Ann Christina Pedersen et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

CA 15-3 is a predictive and prognostic biomarker in patients with metastasized breast cancer undergoing Selective Internal Radiation Therapy

(2013) Yvonne Nadine Fahmueller et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement

(2013) Jeffrey A. Meyerhardt et al.   JOURNAL OF CLINICAL ONCOLOGY

LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both

(2013) Nobuyuki Katakami et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

(2013) Sarah-Jane Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) C. Verslype et al.   ANNALS OF ONCOLOGY

Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials

(2012) Fausto Petrelli et al.   Clinical Lung Cancer

Management of hepatocellular carcinoma: An update

(2011) Jordi Bruix et al.   HEPATOLOGY

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

CA 125 and the detection of recurrent ovarian cancer

(2010) Robert C. Bast   CANCER

Ovarian cancer: relevant therapy, not timing, is paramount

(2010) Robert T Morris et al.   LANCET

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

(2010) Gordon JS Rustin et al.   LANCET

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts

(2009) K Huhtinen et al.   BRITISH JOURNAL OF CANCER

Screening for Ovarian Cancer

(2009) Daniel L. Clarke-Pearson   NEW ENGLAND JOURNAL OF MEDICINE

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

(2008) C. M. Sturgeon et al.   CLINICAL CHEMISTRY

Negative Serum Carcinoembryonic Antigen has Insufficient Accuracy for Excluding Recurrence from Patients with Dukes C Colorectal Cancer: Analysis with Likelihood Ratio and Posttest Probability in a Follow-Up Study

(2008) Masayasu Hara et al.   DISEASES OF THE COLON & RECTUM